TVTX · Categories · Form 4
TVTX - SEC Form 4 insider transactions
Travere Therapeutics Inc. (TVTX) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.
Recent Form 4 for TVTX
- Chief Research Officer Rote William E. exercised 191,500 shares at a strike of $21.40 and sold $13,135,397 worth of shares (209,048 units at $62.83) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 98,197 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- EVP, CHIEF COMMERCIAL OFFICER Heerma Peter exercised 258,189 shares at a strike of $15.69 and sold $17,857,830 worth of shares (283,189 units at $63.06) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 117,066 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- EVP, Head of R&D & CMO Inrig Jula exercised 32,395 shares at a strike of $8.93 and sold $2,785,021 worth of shares (44,674 units at $62.34) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 100,491 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Chief Legal Officer and GC Reed Elizabeth E exercised 37,500 shares at a strike of $15.46 and sold $2,337,695 worth of shares (37,500 units at $62.34) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- CHIEF EXECUTIVE OFFICER Dube Eric M exercised 400,000 shares at a strike of $23.34 and sold $25,390,729 worth of shares (400,000 units at $63.48) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- CHIEF FINANCIAL OFFICER Cline Christopher R. exercised 20,000 shares at a strike of $17.44 and sold $3,148,544 worth of shares (50,508 units at $62.34) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 87,508 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SVP, CHIEF ACCOUNTING OFFICER Calvin Sandra exercised 5,375 shares at a strike of $24.19 and sold $335,005 worth of shares (5,375 units at $62.33) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Director Meckler Jeffrey A exercised 20,000 shares at a strike of $21.98 and sold $1,346,106 worth of shares (20,000 units at $67.31) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- CHIEF FINANCIAL OFFICER Cline Christopher R. sold $42,610 worth of shares (642 units at $66.37), decreasing direct ownership by 0.54% to 118,016 units (SEC Form 4) to cover taxes4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Director Lyons Gary A exercised 10,000 shares at a strike of $17.44 and sold $632,846 worth of shares (10,000 units at $63.28) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- CHIEF MEDICAL OFFICER Inrig Jula gifted 468 shares, decreasing direct ownership by 0.41% to 112,770 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Director Coughlin Timothy exercised 10,000 shares at a strike of $26.52 and sold $500,747 worth of shares (10,000 units at $50.07) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Director Baynes Roy D. exercised 4,500 shares at a strike of $21.38 and sold $225,000 worth of shares (4,500 units at $50.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Director Williams Brinkley Ruth was granted 4,000 shares, increasing direct ownership by 16% to 29,750 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Director Meckler Jeffrey A was granted 4,000 shares, increasing direct ownership by 5% to 91,500 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Director Orwin John A was granted 4,000 shares, increasing direct ownership by 11% to 39,375 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Director Poole Sandra was granted 4,000 shares, increasing direct ownership by 13% to 34,000 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Director Squarer Ron was granted 4,000 shares, increasing direct ownership by 11% to 39,375 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Director Baynes Roy D. was granted 4,000 shares, increasing direct ownership by 11% to 41,500 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Director Lyons Gary A was granted 4,000 shares, increasing direct ownership by 7% to 61,500 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Director Bruhn Suzanne Louise was granted 4,000 shares, increasing direct ownership by 14% to 32,750 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Director Coughlin Timothy was granted 4,000 shares, increasing direct ownership by 8% to 56,250 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Director Coughlin Timothy sold $141,342 worth of shares (3,250 units at $43.49) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 52,250 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Director Baynes Roy D. exercised 4,500 shares at a strike of $18.27 and sold $209,925 worth of shares (4,500 units at $46.65) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Chief Research Officer Rote William E. converted options into 4,250 shares and sold $121,434 worth of shares (2,763 units at $43.95) as part of a pre-agreed trading plan, increasing direct ownership by 1% to 115,474 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Director Meckler Jeffrey A exercised 8,000 shares at a strike of $16.33 and sold $360,000 worth of shares (8,000 units at $45.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Chief Legal Officer and GC Reed Elizabeth E exercised 24,250 shares at a strike of $14.81 and sold $1,092,657 worth of shares (24,250 units at $45.06) as part of a pre-agreed trading plan (SEC Form 4) to satisfy tax liability4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- CHIEF FINANCIAL OFFICER Cline Christopher R. converted options into 4,250 shares and sold $115,368 worth of shares (2,491 units at $46.31) as part of a pre-agreed trading plan, increasing direct ownership by 2% to 118,658 units (SEC Form 4) to cover taxes4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- CHIEF COMMERCIAL OFFICER Heerma Peter sold $101,417 worth of shares (2,174 units at $46.65) and converted options into 4,250 shares, increasing direct ownership by 1% to 140,684 units (SEC Form 4) (withholding obligation)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- CHIEF MEDICAL OFFICER Inrig Jula exercised 24,250 shares at a strike of $18.47 and sold $1,015,086 worth of shares (22,485 units at $45.15) as part of a pre-agreed trading plan, increasing direct ownership by 2% to 113,238 units (SEC Form 4) (for tax liability)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- CHIEF EXECUTIVE OFFICER Dube Eric M converted options into 22,500 shares and sold $988,875 worth of shares (22,500 units at $43.95) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Director Baynes Roy D. exercised 9,750 shares at a strike of $6.82 and sold $431,145 worth of shares (9,750 units at $44.22) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Chief Research Officer Rote William E. sold $355,719 worth of shares (9,100 units at $39.09) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 113,987 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SEC Form 4 filed by Baynes Roy D.4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SEC Form 4 filed by Lyons Gary A4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SEC Form 4 filed by Calvin Sandra4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SEC Form 4 filed by Heerma Peter4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SEC Form 4 filed by Rote William E.4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SEC Form 4 filed by Dube Eric M4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SEC Form 4 filed by Reed Elizabeth E4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SEC Form 4 filed by Cline Christopher R.4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SEC Form 4 filed by Inrig Jula4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SEC Form 4 filed by Baynes Roy D.4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SEC Form 4 filed by Dube Eric M4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SEC Form 4 filed by Reed Elizabeth E4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SEC Form 4 filed by Reed Elizabeth E4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- CHIEF EXECUTIVE OFFICER Dube Eric M exercised 60,000 shares at a strike of $15.46 and sold $1,805,766 worth of shares (60,000 units at $30.10) (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Chief Legal Officer and GC Reed Elizabeth E exercised 10,000 shares at a strike of $19.08 and sold $278,315 worth of shares (10,000 units at $27.83) (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- CHIEF FINANCIAL OFFICER Cline Christopher R. sold $56,168 worth of shares (1,745 units at $32.19), decreasing direct ownership by 2% to 111,226 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- CHIEF MEDICAL OFFICER Inrig Jula sold $57,295 worth of shares (1,779 units at $32.21), decreasing direct ownership by 2% to 105,706 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Chief Legal Officer and GC Reed Elizabeth E sold $96,359 worth of shares (2,994 units at $32.18), decreasing direct ownership by 3% to 105,211 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Chief Research Officer Rote William E. was granted 20,090 shares and sold $409,100 worth of shares (12,446 units at $32.87), increasing direct ownership by 8% to 109,087 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- CHIEF FINANCIAL OFFICER Cline Christopher R. was granted 28,130 shares and sold $232,613 worth of shares (7,242 units at $32.12), increasing direct ownership by 23% to 112,971 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Chief Legal Officer and GC Reed Elizabeth E was granted 25,110 shares and sold $230,461 worth of shares (7,175 units at $32.12), increasing direct ownership by 20% to 108,205 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- CHIEF COMMERCIAL OFFICER Heerma Peter was granted 26,120 shares and sold $234,797 worth of shares (7,310 units at $32.12), increasing direct ownership by 17% to 131,823 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- CHIEF EXECUTIVE OFFICER Dube Eric M was granted 113,800 shares and sold $3,230,316 worth of shares (100,087 units at $32.28), increasing direct ownership by 3% to 432,886 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- CHIEF MEDICAL OFFICER Inrig Jula was granted 28,130 shares and sold $223,427 worth of shares (6,956 units at $32.12), increasing direct ownership by 25% to 107,485 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SVP, CHIEF ACCOUNTING OFFICER Calvin Sandra was granted 15,180 shares and sold $139,176 worth of shares (4,333 units at $32.12), increasing direct ownership by 28% to 49,080 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- CHIEF EXECUTIVE OFFICER Dube Eric M exercised 60,000 shares at a strike of $15.46 and sold $1,805,134 worth of shares (60,000 units at $30.09) (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- Chief Legal Officer and GC Reed Elizabeth E exercised 10,000 shares at a strike of $19.08 and sold $273,420 worth of shares (10,000 units at $27.34) (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)